We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -2.70 | -1.80% | 147.00 | 149.8139 | 146.76 | 149.79 | 9,520,253 | 01:00:00 |
From May 2019 to May 2024
By Tess Stynes
Pfizer Inc. plans to start U.S. shipments of biosimilar Inflectra, its copycat version of Johnson & Johnson's anti-inflammatory drug Remicade, at a 15% discount to Remicade's wholesale prices starting in late November.
Pfizer, which has U.S. commercialization rights to Inflectra, said the estimated wholesale price doesn't include discounts to payers, distributors and others.
Inflectra, developed by South Korea pharmaceutical company Celltrion Inc., received Food and Drug Administration approval earlier this year but faced legal challenges over a patent for Remicade.
Inflectra, the second approved biosimilar treatment in the U.S., is approved to treat rheumatoid arthritis, ulcerative colitis and Crohn's disease.
Write to Tess Stynes at tess.stynes@wsj.com
(END) Dow Jones Newswires
October 17, 2016 17:51 ET (21:51 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
